Published in J Clin Oncol on July 01, 1992
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J (1996) 3.22
Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ (2000) 2.80
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer (2006) 2.75
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest (2001) 2.11
Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg (2002) 1.79
Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol (2000) 1.64
The HER-2/neu oncogene in breast cancer: so what is new? J Clin Oncol (1992) 1.39
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol (2005) 1.33
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med (2008) 1.27
Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res (2003) 1.21
Prevention of mammary carcinogenesis in MMTV-neu mice by cruciferous vegetable constituent benzyl isothiocyanate. Cancer Res (2009) 1.20
Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol (2008) 1.20
Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS One (2012) 1.19
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol (2009) 1.18
Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer (2003) 1.18
A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene (2010) 1.17
Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol (1996) 1.17
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer (1999) 1.14
Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am J Pathol (2002) 1.13
Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol (1996) 1.12
FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res (2010) 1.11
Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res (2005) 1.09
Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer (1994) 1.09
Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep (2012) 1.08
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs (2005) 1.08
Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer (2013) 1.06
Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging (2006) 1.06
C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res (2003) 1.04
Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochim Biophys Acta (2009) 1.03
Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest (2010) 1.02
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer (2008) 0.99
IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma. J Clin Pathol (2005) 0.99
HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer (2007) 0.98
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. Curr Oncol (2009) 0.98
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. BMC Cancer (2007) 0.97
HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer Res (2007) 0.96
Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol (2007) 0.95
Applications of microarray technology in breast cancer research. Breast Cancer Res (2001) 0.95
Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer (2014) 0.95
External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. Proc Natl Acad Sci U S A (2002) 0.94
Prognostic and Predictive Factors for Breast Cancer. Breast Cancer (1995) 0.94
Caspase cleavage of HER-2 releases a Bad-like cell death effector. J Biol Chem (2008) 0.92
Testing for HER2 in Breast Cancer: A Continuing Evolution. Patholog Res Int (2010) 0.92
ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases. Breast Cancer (Auckl) (2013) 0.91
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study. BMC Cancer (2013) 0.90
c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer (1999) 0.89
High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol (2011) 0.88
Treatment strategy for HER2-positive breast cancer. Int J Clin Oncol (2010) 0.87
Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification. Am J Pathol (2002) 0.87
Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn (2008) 0.87
Breast cancer subtypes and survival in chinese women with operable primary breast cancer. Chin J Cancer Res (2011) 0.85
Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology (1998) 0.84
Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.83
HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy. J Cancer Res Clin Oncol (2007) 0.83
The epidermal growth factor receptor family in breast cancer. Onco Targets Ther (2008) 0.83
Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol (2006) 0.83
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer. Curr Oncol (2009) 0.83
Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women. Breast Cancer Res (2005) 0.83
Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. Am J Pathol (1998) 0.83
Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways. Breast Cancer Res (2006) 0.82
Protein kinases C isozymes are differentially expressed in human breast carcinomas. Life Sci (2009) 0.81
The role and clinical relevance of disseminated tumor cells in breast cancer. Cancers (Basel) (2014) 0.81
Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index. Support Care Cancer (2009) 0.80
Prognostic factors and recurrence in breast cancer: experience at the national cancer institute of Mexico. ISRN Oncol (2012) 0.80
Redox potential ultrasensitive nanoparticle for the targeted delivery of camptothecin to HER2-positive cancer cells. Mol Pharm (2014) 0.79
Evaluation of intratumoral HER-2 heterogeneity by fluorescence in situ hybridization in invasive breast cancer: a single institution study. J Korean Med Sci (2011) 0.79
Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer. Chemother Res Pract (2011) 0.79
Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay. Indian J Med Res (2012) 0.78
Toward checkmate: biology and breast cancer therapy for the new millennium. Invest New Drugs (1999) 0.78
Divide and conquer: progress in the molecular stratification of cancer. Yonsei Med J (2009) 0.77
Alternative targeted therapy for early Her2 positive breast cancer. Gland Surg (2013) 0.77
Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives. Onco Targets Ther (2016) 0.77
Adenovirus-directed expression of Q227L-G alpha(s) inhibits growth of established tumors of later-stage human breast cancer cells in athymic mice. Proc Natl Acad Sci U S A (2002) 0.76
Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. J Cancer Res Clin Oncol (2015) 0.76
Biological indices in the assessment of breast cancer. Clin Mol Pathol (1995) 0.75
Infracentimetric HER-2 positive breast tumours-review of the literature. Ecancermedicalscience (2015) 0.75
Recent advances in the treatment of breast cancer. Postgrad Med J (1994) 0.75
A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation. Onco Targets Ther (2016) 0.75
Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen. Br J Cancer (1993) 0.75
Functional consequences of cyclin D1 overexpression in human mammary luminal epithelial cells. Clin Exp Metastasis (1998) 0.75
Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2(+) mammary cancer. Oncoimmunology (2015) 0.75
Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan. Mol Clin Oncol (2015) 0.75
Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients. Breast Cancer (Dove Med Press) (2014) 0.75
The role of oncogenes in drug resistance. Cytotechnology (1998) 0.75
Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. Drugs Aging (2015) 0.75
High-grade breast cancers include both highly sensitive and highly resistant subsets to cytotoxic chemotherapy. J Cancer Res Clin Oncol (2010) 0.75
Distinct luminal-type mammary carcinomas arise from orthotopic Trp53-null mammary transplantation of juvenile versus adult mice. Cancer Res (2014) 0.75
Development of Companion Diagnostics. Semin Nucl Med (2016) 0.75
Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA). J Cancer Res Clin Oncol (2005) 0.75
Molecular genetics complexity impeding research progress in breast and ovarian cancers. Mol Clin Oncol (2017) 0.75
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Deficits in psychologic and classroom performance of children with elevated dentine lead levels. N Engl J Med (1979) 9.80
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18
The role of small nuclear ribonucleoprotein particles in pre-mRNA splicing. Nature (1987) 8.28
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol (2007) 7.33
A role for exon sequences and splice-site proximity in splice-site selection. Cell (1986) 6.41
Analysis of survival by tumor response. J Clin Oncol (1983) 5.91
The protein Aly links pre-messenger-RNA splicing to nuclear export in metazoans. Nature (2000) 5.57
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol (2005) 5.41
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol (2001) 5.31
Intron sequences involved in lariat formation during pre-mRNA splicing. Cell (1985) 5.30
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med (1991) 5.22
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
Splicing is required for rapid and efficient mRNA export in metazoans. Proc Natl Acad Sci U S A (1999) 4.26
SR proteins promote the first specific recognition of Pre-mRNA and are present together with the U1 small nuclear ribonucleoprotein particle in a general splicing enhancer complex. Mol Cell Biol (1994) 4.25
Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med (1995) 4.03
An ATP-independent complex commits pre-mRNA to the mammalian spliceosome assembly pathway. Genes Dev (1991) 3.99
Pre-mRNA splicing and mRNA export linked by direct interactions between UAP56 and Aly. Nature (2001) 3.94
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood (2001) 3.93
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet (2000) 3.79
The splicing factor BBP interacts specifically with the pre-mRNA branchpoint sequence UACUAAC. Cell (1997) 3.68
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst (1998) 3.50
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet (1999) 3.50
Limitation of medical care: an ethnographic analysis. J Clin Ethics (1993) 3.45
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood (2001) 3.24
A novel set of spliceosome-associated proteins and the essential splicing factor PSF bind stably to pre-mRNA prior to catalytic step II of the splicing reaction. EMBO J (1994) 3.17
Protein components specifically associated with prespliceosome and spliceosome complexes. Genes Dev (1992) 3.16
Evidence that sequence-independent binding of highly conserved U2 snRNP proteins upstream of the branch site is required for assembly of spliceosomal complex A. Genes Dev (1996) 3.06
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Evaluation of the effect of WIC supplemental feeding on birth weight. J Am Diet Assoc (1982) 2.92
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
A functional association between the 5' and 3' splice site is established in the earliest prespliceosome complex (E) in mammals. Genes Dev (1993) 2.83
The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer (1997) 2.75
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72
Differential binding of heterogeneous nuclear ribonucleoproteins to mRNA precursors prior to spliceosome assembly in vitro. Mol Cell Biol (1992) 2.66
A potential role for U2AF-SAP 155 interactions in recruiting U2 snRNP to the branch site. Mol Cell Biol (1998) 2.62
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol (1989) 2.57
Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol (2001) 2.37
Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev (1998) 2.30
Identification of proteins that interact with exon sequences, splice sites, and the branchpoint sequence during each stage of spliceosome assembly. Mol Cell Biol (1996) 2.29
Who gets chemotherapy for metastatic lung cancer? Chest (2000) 2.27
Functional association of U2 snRNP with the ATP-independent spliceosomal complex E. Mol Cell (2000) 2.27
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol (2008) 2.26
A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med (2000) 2.17
Resolution of the mammalian E complex and the ATP-dependent spliceosomal complexes on native agarose mini-gels. RNA (1999) 2.06
Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol (2001) 2.05
Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol (1998) 2.05
Direct interactions between pre-mRNA and six U2 small nuclear ribonucleoproteins during spliceosome assembly. Mol Cell Biol (1994) 2.03
Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol (2002) 2.03
Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol (1991) 2.02
Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia (2000) 2.02
Outcome of pregnancy in survivors of Wilms' tumor. JAMA (1987) 2.00
Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 2.00
A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med (1994) 1.97
Identification of both shared and distinct proteins in the major and minor spliceosomes. Science (1999) 1.96
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol (2000) 1.92
Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol (2000) 1.91
Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys (1993) 1.90
Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke (1992) 1.89
Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med (1991) 1.88
Evidence that U5 snRNP recognizes the 3' splice site for catalytic step II in mammals. EMBO J (1997) 1.85
An X-ray and electron microscope study of tropomyosin. Biochem J (1948) 1.85
A two-step mechanism for 5' and 3' splice-site pairing. Nature (1995) 1.85
Identification of a functional mammalian spliceosome containing unspliced pre-mRNA. Proc Natl Acad Sci U S A (1988) 1.85
Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer (1997) 1.82
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol (2000) 1.81
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol (2012) 1.79
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol (2000) 1.79
Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet (2001) 1.79
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol (1999) 1.77